Loading company…
Neuway Pharma develops mRNA-based therapies for rare central nervous system diseases using its EnPC delivery platform.
Based in Bonn, Germany, Neuway Pharma was founded in 2014 as a spin-off from Life Science Inkubator (LSI) GmbH. In August 2023 it raised Series B funding from ELBE Beteiligungsgesellschaft mbH, with participation from Wellington Partners, PANDA GmbH, Kfw and LSI-Pre-Seed-Fonds GmbH. Its lead candidate targets Metachromatic Leukodystrophy, a rare lysosomal storage disorder.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in